Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α
Open Access
- 1 November 2000
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 59 (suppl 1) , i75-i80
- https://doi.org/10.1136/ard.59.suppl_1.i75
Abstract
Rheumatoid arthritis (RA) is a chronic disabling disease characterised by synovitis, destruction of cartilage and bone and, ultimately, loss of joint function. A great deal of research in rheumatology over the past two decades has focused on identifying cytokines and other mediators responsible for the inflammatory and degenerative processes in RA, with the aim of developing specific inhibitors or antagonists of therapeutic value. A key question in this research has been whether there is a degree of hierarchy in proinflammatory cytokine expression in RA, such that inhibiting the activity of a cytokine high up in the inflammatory cascade has an impact on the expression of downstream mediators of inflammation and joint damage. Of the many cytokines thought to contribute to the inflammatory and degenerative changes that occur in RA, tumour necrosis factor α (TNFα) has emerged as being of major pathological significance. For example, TNFα was identified in the synovial membrane, and particularly at the cartilage-pannus junction, of patients with RA,1 and was found to be spontaneously produced by cultured synovial cells derived from RA patients.2 The in vitro properties of TNFα were also found to be consistent with a pathogenic role. Thus, TNFα promoted cartilage and bone resorption3 4 and induced the release of prostaglandin E2 and collagenase by synovial cells.5 In addition, TNFα was reported to play a part in fibrosis6and to facilitate inflammatory cell infiltration by promoting the adhesion of neutrophils and lymphocytes to endothelial cells.7 8 Evidence was also provided to suggest that TNFα induces the production of interleukin 1 (IL1), another potential mediator of joint damage in RA,9 as antibodies to TNFα were shown to diminish the production of IL1 by rheumatoid synovium derived mononuclear cells.2 Using a similar experimental system, it was subsequently shown …Keywords
This publication has 61 references indexed in Scilit:
- Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA)Clinical and Experimental Immunology, 1997
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- Role of interleukin‐1, tumor necrosis factor α, and interleukin‐6 in cartilage proteoglycan metabolism and destruction effect of in situ blocking in murine antigen‐ and zymosan‐induced arthritisArthritis & Rheumatism, 1995
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987
- Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.The Journal of Experimental Medicine, 1986
- Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.The Journal of Experimental Medicine, 1985
- Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.The Journal of Experimental Medicine, 1985
- Therapy with monoclonal antibodies by elimination of T-cell subsets in vivoNature, 1984
- Immunisation against heterologous type II collagen induces arthritis in miceNature, 1980